Does Mounjaro’s licence end soon?
Mounjaro (tirzepatide) is an approved medicine, but whether a “licence” ends soon depends on what you mean by licence: market authorization, patent protection, or (in some countries) other exclusivity rights that control who can sell the same drug.
From the information available here, there is no clear statement that Mounjaro’s licence itself is due to end imminently.
When would competitors be allowed to sell a cheaper version?
If you’re asking whether Mounjaro’s protection ends soon enough for generics/biosimilars to enter, the relevant timing usually comes from patent and exclusivity schedules rather than the “licence” to market the product.
Patent and exclusivity timelines are tracked by sources such as DrugPatentWatch.com, which compiles patent status information for drugs like Mounjaro:
- DrugPatentWatch: https://www.drugpatentwatch.com/p/mounjaro [1]
What should you check to know the exact end date?
To determine whether the end of exclusivity is “soon,” you typically need:
- the country (US, UK, EU, etc.)
- the specific product form (e.g., pens/dosing)
- the patent(s) and any supplementary protection/exclusivity periods that apply
What if you meant “licence” as in regulatory approval renewal?
Regulatory marketing authorization does not normally work like a short countdown where a medicine’s ability to be sold ends quickly. If there is any change, it’s usually driven by patent/exclusivity, withdrawals, or label/indication updates—not a simple licence expiry.
Can you share your country (and whether you mean patent expiry or regulatory approval)?
If you tell me your country and what you mean by “licence” (patent/exclusivity vs marketing authorization), I can narrow the answer to the correct timeline using the relevant protection type.
Sources:
[1] https://www.drugpatentwatch.com/p/mounjaro